ライフサイエンスコーパス: human monoclonal antibody

1 CSPG4-specific chimeric, humanized, or fully human monoclonal antibody.

2 antification of somatropin and a therapeutic human monoclonal antibody.

3 t manner by IVIG, F(ab)2-IVIG and irrelevant human monoclonal antibody.

4 the epitopes of several broadly neutralizing human monoclonal antibodies.

5 epitope sites targeted by virus neutralising human monoclonal antibodies.

6 he isolation and characterization of a fully human monoclonal antibody (1C1) that selectively binds b

7 Human monoclonal antibody 2219 is a neutralizing antibod

8 ied as the epitope of the HIV-1 neutralizing human monoclonal antibody 2F5 (MAb 2F5).

9 The human monoclonal antibody 2F5 neutralizes primary human

10 om the polyreactive and broadly neutralizing human monoclonal antibody 2F5 was targeted into the mous

11 The broadly neutralizing human monoclonal antibody 2F5 was used to select for vir

12 with the corresponding broadly neutralizing human monoclonal antibody 2F5, provides a target for str

13 gnition epitope for the broadly neutralizing human monoclonal antibody 2F5.

14 gp41 is a target of two broadly neutralizing human monoclonal antibodies, 2F5 and 4E10, and is an imp

15 lasmablast enrichment technique to isolate a human monoclonal antibody, 46B8 that neutralizes all IBV

16 plasma, HIV immunoglobulin, soluble CD4, and human monoclonal antibodies 4E10, 2F5, and b12.

17 o phosphatidylinositol phosphate (PIP) and a human monoclonal antibody (4E10) that is known to have b

18 ed gp41-specific cross-reactive neutralizing human monoclonal antibodies, 4E10 and 2F5, target linear

19 r actions of two rare, broadly neutralizing, human monoclonal antibodies, 4E10 and 2F5, which target

20 Here we show that the DENV-specific human monoclonal antibody 5J7 is exceptionally potent, n

21 We isolated human monoclonal antibody 5J8, which neutralized a broad

22 that the hemagglutinin (HA) stalk-targeting human monoclonal antibody 81.39a effectively neutralized

23 ated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects t

24 Human monoclonal antibodies (Abs) to the CD4 binding dom

25 A combination of human monoclonal antibodies, actoxumab and bezlotoxumab,

26 Neutralizing human monoclonal antibodies against alpha-toxin (AT) and

27 -controlled study of two neutralizing, fully human monoclonal antibodies against C. difficile toxins

28 , we identified a panel of macropinocytosing human monoclonal antibodies against CD46, a negative reg

29 We have previously identified neutralizing human monoclonal antibodies against Nipah virus (NiV) an

30 Production of human monoclonal antibodies against Stx, which are highl

31 We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid level

32 We aimed to compare panitumumab, a fully human monoclonal antibody against EGFR, plus radiotherap

33 Then we report the identification of HS20, a human monoclonal antibody against GPC3, which preferenti

34 trial evaluated the safety and efficacy of a human monoclonal antibody against interleukin-12 (anti-i

35 hn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and int

36 sed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 recepto

37 the development of a highly effective fully human monoclonal antibody against Jagged1 (clone 15D11).

38 We assessed the effects of AMG 145, a human monoclonal antibody against PCSK9, in patients wit

39 Evolocumab, a fully human monoclonal antibody against proprotein convertase

40 AMG 145, a fully human monoclonal antibody against proprotein convertase

41 randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of

42 vestigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of

43 vestigated the ability of denosumab, a fully human monoclonal antibody against receptor activator of

44 We generated a human monoclonal antibody against scavenger receptor cla

45 activity of 80R immunoglobulin G1 (IgG1), a human monoclonal antibody against severe acute respirato

46 5C12 HuMAb is a human monoclonal antibody against the A subunit of Shiga

47 the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for

48 the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in

49 Ustekinumab is a fully human monoclonal antibody against the p40 subunit of int

50 Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-

51 Ganitumab is a fully human monoclonal antibody against type-1 insulin-like gr

52 Evolocumab is a fully human, monoclonal antibody against PCSK9 that reduces lo

53 A ligand-mimetic human monoclonal antibody AL-57 (activated LFA-1 clone 5

54 oires offers a novel route to discover fully human monoclonal antibodies and identify antigens of pot

55 sensitivity to neutralizing patient IgG and human monoclonal antibodies AR3A and AR4A and (ii) incre

56 upport further development of m336 and other human monoclonal antibodies as potential therapeutics fo

57 bust system for the discovery of therapeutic human monoclonal antibodies; as a surrogate readout of t

58 We investigated whether a human monoclonal antibody (AVP-21D9) to protective antig

59 l administration of the broadly neutralizing human monoclonal antibody b12 can protect macaques from

60 The human monoclonal antibody b12 recognizes a conserved epi

61 Bezlotoxumab, a human monoclonal antibody, binds to C. difficile toxin B

62 We have developed a method to generate human monoclonal antibodies by selecting phage antibody

63 We have previously described a human monoclonal antibody called KM33 that blocks these

64 Selection of human monoclonal antibodies can identify immunodominant

65 Several human monoclonal antibodies can neutralize a range of hu

66 We describe a human monoclonal antibody, CH65, obtained by isolating r

67 ve immunization with combinations containing human monoclonal antibodies completely prevented infecti

68 port the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing

69 Here, we report human monoclonal antibodies, CR8033, CR8071, and CR9114,

70 The human monoclonal antibody, D5, binds to this target and

71 s with a potency that rivals that of several human monoclonal antibodies, demonstrating that computat

72 The fully human monoclonal antibody denosumab (formerly known as A

73 HLA class I-specific human monoclonal antibodies derived from women sensitize

74 We assessed ustekinumab, a human monoclonal antibody directed against these cytokin

75 S for simultaneous detection of the residual human monoclonal antibody drug and endogenous human IgG

76 The human monoclonal antibody Fab X5 neutralizes a broad ran

77 Among a panel of 18 dengue virus-reactive human monoclonal antibodies, four groups of antibodies w

78 isplay to produce a panel of chimeric rabbit/human monoclonal antibody fragments (both Fab and scFv)

79 , we isolated a panel of dengue prM-specific human monoclonal antibodies from individuals after infec

80 We derived human monoclonal antibodies from persons who received th

81 agents against ZIKV, we isolated a panel of human monoclonal antibodies from subjects that were prev

82 We derived human monoclonal antibodies from the bone marrow of a pa

83 Further, by using TG2-specific human monoclonal antibodies generated from intestinal pl

84 A fully human monoclonal antibody has been isolated that binds t

85 The human monoclonal antibody HC-1 recognizes a conformation

86 Recombinant human monoclonal antibodies (hmAb) against gliadin are p

87 trated that DENV serotype 2 (DENV2)-specific human monoclonal antibody (HMAb) 2D22 is therapeutic in

88 Human monoclonal antibody (hMAb) targeting the hemagglut

89 roadly cross-reactive HIV-neutralizing CD4bs human monoclonal antibody (hmAb), m18.

90 was reported to resist neutralization by the human monoclonal antibodies (hmAbs) 80R and S3.1, which

91 e identification and characterization of new human monoclonal antibodies (hMAbs) able to neutralize p

92 Five human monoclonal antibodies (HMAbs) are described that c

93 In the current study, we obtained human monoclonal antibodies (hMAbs) directly from antibo

94 roduction and analysis of HIV-1 Env-specific human monoclonal antibodies (hMAbs) isolated from vaccin

95 nistic studies with anti-dengue virus (DENV) human monoclonal antibodies (hMAbs) provide a rational a

96 tro against a panel of 12 well-characterized human monoclonal antibodies (HMAbs) targeting diverse E1

97 Previously, we identified 10 human monoclonal antibodies (HMAbs) that bind E2 glycopr

98 Epitope mapping of human monoclonal antibodies (HMAbs) that bind to an adja

99 erplay between these antibodies, we isolated human monoclonal antibodies (HMAbs) to aa 412 to 423, de

100 1E2 glycoproteins, as defined in part by HCV human monoclonal antibodies (HMAbs) to conformational ep

101 Characterization of a panel of human monoclonal antibodies (HMAbs) to HCV by competitio

102 omplementary strategy is to use neutralizing human monoclonal antibodies (HMAbs) to prevent acute inf

103 A panel of immunoglobulin G1 human monoclonal antibodies (HMAbs) to three immunogenic

104 Human monoclonal antibodies (HMAbs) with neutralizing ca

105 lobal E2 alanine scanning with a panel of 16 human monoclonal antibodies (hmAbs), resulting in an unp

106 ation by chronic-phase patient sera and lead human monoclonal antibodies (HMAbs).

107 tocol for the production of antigen-specific human monoclonal antibodies (hmAbs).

108 d binding affinity of a panel of anti-HCV E2 human monoclonal antibodies (HMAbs).

109 By using HuMAb-Mouse (Medarex) animals, human monoclonal antibodies (Hu-MAbs) were developed aga

110 We investigated the efficacy of specific human monoclonal antibodies (HuMab) and alpaca polyclona

111 igational product containing a mixture of 26 human monoclonal antibodies (HuMAbs) against mature viri

112 ed with OspA from B. burgdorferi to generate human monoclonal antibodies (HuMabs) against OspA.

113 n and preclinical evaluation of neutralizing human monoclonal antibodies (HuMAbs) against the Shiga t

114 pursue this treatment modality, we developed human monoclonal antibodies (HuMAbs) directed against th

115 to express 3 human rabies virus-neutralizing human monoclonal antibodies (huMAbs) in a rhabdovirus ve

116 administration of Shiga toxin (Stx)-specific human monoclonal antibodies (HuMAbs) is considered a pro

117 We have previously shown that Stx2-specific human monoclonal antibodies (HuMAbs) protect mice and pi

118 In this report we describe fully human monoclonal antibodies (HuMAbs) that neutralize the

119 neutralizing activities; they are the first human monoclonal antibodies identified against these vir

120 fragments of antigen binding (Fabs) from two human monoclonal antibodies, IgG-94 and IgG-RC, isolated

121 uid-liquid phase separation in a solution of human monoclonal antibody, IgG2, and the effects of huma

122 e expression of an EGFP-labeled single-chain human monoclonal antibody, IK17, which binds to MDA-LDL,

123 4 and their sensitivity to neutralization by human monoclonal antibody immunoglobulin G1b12 and, to a

124 e the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patien

125 Characterization of human monoclonal antibodies is providing considerable in

126 The isolation of human monoclonal antibodies is providing important insig

127 CR4354, a human monoclonal antibody isolated from a patient, neutr

128 d to the Fab fragment of 1G2, a neutralizing human monoclonal antibody isolated from a seropositive s

129 n addition, the technological convergence of human monoclonal antibody isolation, structural biology,

130 ve broadly cross-reactive HIV-1-neutralizing human monoclonal antibodies known to date, X5 is the onl

131 A neutralizing human monoclonal antibody, KZ52, protects guinea pigs fr

132 A human monoclonal antibody, LymphoStat-B, specific for hu

133 AGMs showed that the therapeutic window for human monoclonal antibody m102.4, previously shown to re

134 Here we report a human monoclonal antibody, m826, that binds to H7 hemagg

135 We solved the crystal structure of human monoclonal antibody (MAb) 2158, which targets a co

136 unique epitope for the broadly neutralizing human monoclonal antibody (MAb) 2G12 on the gp120 surfac

137 The human monoclonal antibody (MAb) A32 is a nonneutralizing

138 Competitive binding of the human monoclonal antibody (mAb) LE2E9 revealed overlappi

139 including an A32-like epitope, recognized by human monoclonal antibody (MAb) N60-i3, and a hybrid A32

140 Ustekinumab is a fully human monoclonal antibody (mAb) that binds specifically

141 first to enter the clinic, ustekinumab, is a human monoclonal antibody (mAb) that binds to the p40 su

142 ve at blocking opsonic killing mediated by a human monoclonal antibody (mAb) to native PNAG than it w

143 evolution, and structure of a broad-spectrum human monoclonal antibody (mAb), MEDI8852, effectively r

144 Further, these viruses were neutralized by a human monoclonal antibody (MAb), S230.15, but the parent

145 We isolated a human monoclonal antibody (mAb), ZKA190, that potently c

146 Use of the human monoclonal antibody, MAB-T88, did not improve the

147 Two human monoclonal antibodies, mAb100 and mAb114, in combi

148 Two human monoclonal antibodies (MAbs) (2F5 and 4E10) agains

149 The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both ta

150 We isolated a large panel of human monoclonal antibodies (mAbs) against BDBV glycopro

151 We screened a panel of mouse and human monoclonal antibodies (MAbs) against chikungunya v

152 virus-like particles (VLPs) to isolate seven human monoclonal antibodies (MAbs) against the CHIKV env

153 We tested whether human monoclonal antibodies (MAbs) against the three maj

154 t into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a prev

155 1 due to modest potency and breadth of early human monoclonal antibodies (MAbs) and perceived insurmo

156 n-specific sorting, we isolated Env-specific human monoclonal antibodies (MAbs) and studied the clona

157 he genes encoding broadly HIV-1-neutralizing human monoclonal antibodies (MAbs) are highly divergent

158 Human monoclonal antibodies (mAbs) are under development

159 To guide vaccine design, we assessed whether human monoclonal antibodies (MAbs) b12 and b6 against th

160 influenza virus hemagglutinin (HA)-reactive human monoclonal antibodies (MAbs) by hybridoma technolo

161 We characterized human monoclonal antibodies (MAbs) cloned from influenza

162 RECENT FINDINGS: Human monoclonal antibodies (mAbs) derived from rheumati

163 Fully human monoclonal antibodies (mAbs) derived from transgen

164 Human monoclonal antibodies (mAbs) designed for immunoth

165 Here we describe the detailed analysis of human monoclonal antibodies (MAbs) directed against HCV

166 Although rare human monoclonal antibodies (mAbs) exist that broadly ne

167 We report here the identification of human monoclonal antibodies (MAbs) from a large nonimmun

168 The first uses human monoclonal antibodies (MAbs) generated against the

169 Although highly inhibitory murine and human monoclonal antibodies (mAbs) have been generated,

170 tion of a large panel of naturally occurring human monoclonal antibodies (MAbs) obtained from subject

171 Human monoclonal antibodies (MAbs) specific for HIV-2 V3

172 The selection of human monoclonal antibodies (MAbs) specific for human im

173 Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV gly

174 ly-N-acetylated glucosamine (PNAG) by use of human monoclonal antibodies (MAbs) specific for such epi

175 For Pseudomonas aeruginosa, human monoclonal antibodies (mAbs) targeting the Psl bio

176 d from sorted single ASCs to produce over 50 human monoclonal antibodies (mAbs) that bound to the thr

177 We isolated and characterized human monoclonal antibodies (mAbs) that neutralize CHIKV

178 We identified human monoclonal antibodies (mAbs) that neutralize genet

179 Human monoclonal antibodies (MAbs) that neutralize SARS-

180 Two human monoclonal antibodies (MAbs) that neutralized DENV

181 ated from a single donor 13 new neutralizing human monoclonal antibodies (mAbs) that recognize the RS

182 Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed th

183 tro activities and efficacies in mice of two human monoclonal antibodies (MAbs) to type 8 PS, NAD (Ig

184 We report 3 LukAB-specific human monoclonal antibodies (mAbs) with distinct mechani

185 d neutralization properties of 15 anti-HIV-2 human monoclonal antibodies (MAbs), 14 of which were new

186 iously characterized a panel of neutralizing human monoclonal antibodies (MAbs), but the majority of

187 Several neutralizing human monoclonal antibodies (mAbs), including m336, a ge

188 We identified three human monoclonal antibodies (MAbs), m336, m337, and m338

189 ultaneous quantitation of two coadministered human monoclonal antibodies (mAbs), mAb-A and mAb-B of I

190 Using fully human monoclonal antibodies (MAbs), we now have shown th

191 for neutralizing antibodies in studies using human monoclonal antibodies (MAbs).

192 Human monoclonal antibodies may be a useful adjunct to f

193 These data suggest that the 80R human monoclonal antibody may be a useful viral entry in

194 r and suggest that inhibition of CTGF with a human monoclonal antibody may control primary and metast

195 We have developed a fully human monoclonal antibody, MEDI-575, that selectively bi

196 We show that the human monoclonal antibody, MEDI1912, selected against ne

197 rted the isolation and characterization of 2 human monoclonal antibodies neutralizing CHIKV in vitro:

198 s a neutralizing anti-interleukin-13 (IL-13) human monoclonal antibody obtained from a phage display

199 robust SCID mouse-based method for isolating human monoclonal antibodies of desired specificity from

200 erotypic neutralizing epitopes recognized by human monoclonal antibodies onto the surface of the VP8*

201 The human monoclonal antibody opicinumab (BIIB033, anti-LING

202 sensitive PDGF D sandwich ELISA using fully human monoclonal antibodies, PDGF D was detected at elev

203 argeted liposomal nanoprobe by conjugating a human monoclonal antibody, PGN635 that specifically targ

204 ecognized by a recently discovered family of human monoclonal antibodies (PGT151-PGT158).

205 We have previously shown that Stx-specific human monoclonal antibodies protect STEC-infected animal

206 We found that human monoclonal antibodies recognized the Sa antigenic

207 a single-chain variable fragment of the 17b human monoclonal antibody recognizing a highly conserved

208 lly, neutralizing M-CSF activity via a novel human monoclonal antibody reduced the CD14(+)CD16(+) mon

209 es and provide a better understanding of the human monoclonal antibody response to influenza in the c

210 The human monoclonal antibody rHIgM22 enhances remyelination

211 the few known potent broadly cross-reactive human monoclonal antibodies, scFv X5, could be improved

212 -B12, and -B35 expression on platelets using human monoclonal antibodies specific for these antigens.

213 safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-ce

214 Ipilimumab, a human monoclonal antibody targeted against cytotoxic T-l

215 Fully human monoclonal antibodies targeting CTLA-4 have been s

216 The efficacy of TCN-032, a human monoclonal antibody targeting a conserved epitope

217 Ofatumumab (HuMax-CD20) is a human monoclonal antibody targeting a distinct small-loo

218 Panitumumab, a fully human monoclonal antibody targeting the epidermal growth

219 Panitumumab, a fully human monoclonal antibody targeting the epidermal growth

220 To our knowledge, these are the first fully human monoclonal antibodies that are specific to integri

221 Isolation of these antibodies as human monoclonal antibodies that block virus binding and

222 rated and characterized five different fully human monoclonal antibodies that bound to and neutralize

223 also make possible the rapid development of human monoclonal antibodies that could become a potent i

224 Here we show that a combination of human monoclonal antibodies that cross-react with the gl

225 Here, we describe a set of human monoclonal antibodies that define what is, to the

226 Many human monoclonal antibodies that neutralize multiple cla

227 Here we report the isolation of human monoclonal antibodies that recognize erythrocytes

228 Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphoc

229 Conatumumab is a fully human monoclonal antibody that binds to and activates hu

230 Rituximab is a chimeric murine/human monoclonal antibody that binds to CD20 on B lympho

231 PF-00547659 is a fully human monoclonal antibody that binds to human mucosal ad

232 Panitumumab, a human monoclonal antibody that binds to the epidermal gr

233 Ustekinumab is a human monoclonal antibody that binds to the shared p40 s

234 Adalimumab is a fully human monoclonal antibody that binds tumor necrosis fact

235 ment after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways.

236 Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lympho

237 Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and

238 Ustekinumab is a human monoclonal antibody that inhibits receptor-binding

239 We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin g

240 Canakinumab, a human monoclonal antibody that neutralizes interleukin-1

241 This drug, belimumab (Benlysta), is a human monoclonal antibody that neutralizes the B-cell su

242 dy was undertaken to investigate whether the human monoclonal antibody that neutralizes transforming

243 ule (V1V2ZM109-1FD6) in complex with 830A, a human monoclonal antibody that recognizes a V1V2 epitope

244 Sirukumab, a human monoclonal antibody that selectively binds to the

245 BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits inte

246 re we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggre

247 Rilotumumab is a fully human monoclonal antibody that selectively targets the l

248 le-chain variable region construct of 17b, a human monoclonal antibody that targets a conserved CD4-i

249 MEDI4893 is a neutralizing human monoclonal antibody that targets alpha-toxin (AT)

250 PET/NIRF) imaging agents, using 5B1, a fully human monoclonal antibody that targets CA19.9, a well-es

251 Panitumumab is a fully human monoclonal antibody that targets EGFR.

252 vascular risk indicates that canakinumab, a human monoclonal antibody that targets IL-1beta, markedl

253 5B1 is a fully human, monoclonal antibody that has shown promise for th

254 Rilotumumab is a fully human, monoclonal antibody that neutralises HGF.

255 model in humanized mice and used it to test human monoclonal antibody therapy.

256 ires can be mined for the discovery of fully human monoclonal antibodies to B-CLL cell-surface antige

257 We generated a total of 63 new human monoclonal antibodies to compare the B-cell respon

258 In this study, we have generated a panel of human monoclonal antibodies to dengue virus.

259 We evaluated the therapeutic activity of human monoclonal antibodies to DENV EDE for their abilit

260 readth of the recently isolated neutralizing human monoclonal antibodies to HIV-1 have stimulated int

261 We identify human monoclonal antibodies to O-antigens that are highl

262 blished phase I and II trials with two fully human monoclonal antibodies to PCSK9 have provided compr

263 o review the phase 1 and 2 trials with fully human monoclonal antibodies to proprotein convertase sub

264 CBH-2 is a neutralizing human monoclonal antibody to a domain B epitope that is

265 ite the clinical validation of this model, a human monoclonal antibody to CA19.9 (a highly visible bu

266 Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23, a protein expressed o

267 In addition, treatment with a human monoclonal antibody to HCMV glycoprotein B rescues

268 maturation, and characterization of a fully human monoclonal antibody to human NKG2D.

269 We have isolated a human monoclonal antibody to IL-17A (CAT-2200) that can

270 Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein convertas

271 In phase 1 studies, a human monoclonal antibody to PCSK9, AMG145, was well tol

272 assessed the effects of evolocumab, a fully human monoclonal antibody to PCSK9, on Lp(a), the relati

273 AMG 145, a fully human monoclonal antibody to PCSK9, prevents PCSK9/LDL-R

274 In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels

275 SAR236553 is a fully human monoclonal antibody to PCSK9.

276 A second monoclonal antibody [PRM1 (human monoclonal antibody to PR)], which recognizes part

277 Evolocumab, a fully human monoclonal antibody to proprotein convertase subti

278 ts were passively immunized with AVP-21D9, a human monoclonal antibody to protective antigen (PA), at

279 Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacol

280 Denosumab is an investigational fully human monoclonal antibody to receptor activator of nucle

281 Denosumab, a fully human monoclonal antibody to receptor activator of nucle

282 The human monoclonal antibody to serotype 8 pneumococcal cap

283 ty of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the in

284 The potential therapeutic activity of a human monoclonal antibody to the human interleukin-12 p4

285 Denosumab is a fully human monoclonal antibody to the receptor activator of n

286 Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-alpha

287 activity as an immunogen, we generated fully human monoclonal antibodies using the XenoMouse(TM) plat

288 The fully human monoclonal antibody ustekinumab is an efficacious

289 t of cell culture-grown HCV infectivity by a human monoclonal antibody was also observed.

290 By screening a large number of human monoclonal antibodies, we have found that IgM anti

291 of several neutralizing and nonneutralizing human monoclonal antibodies were also determined, which

292 tralize inhibitory RGMa, clinically relevant human monoclonal antibodies were systemically administer

293 Purified HCV E2-specific human monoclonal antibodies were used to further verify

294 Cross-reactivity was studied using a human monoclonal antibody which inhibits allergic patien

295 ZIKV nonstructural protein 1 (NS1)-specific human monoclonal antibody, which we used to develop an N

296 lated and characterized two protective fully human monoclonal antibodies with specificity for protect

297 ration-dependent self-interactions for three human monoclonal antibodies with unique solution behavio

298 Here we present a broadly neutralizing human monoclonal antibody with an unusual binding modali

299 and identified a high affinity, allosteric, human monoclonal antibody, XMetA, which mimicked the glu

300 ent of a highly therapeutic and neutralizing human monoclonal antibody, ZIKV-117.